Advertisement

Index by author

October 01, 1989; Volume 36,Issue 4

A

  1. Alderson, B

    1. Direct inhibition of inositol-1,4,5-trisphosphate-induced Ca2+ release from brain microsomes by K+ channel blockers.
      P Palade, C Dettbarn, P Volpe, B Alderson and A S Otero
      Molecular Pharmacology October 1989, 36 (4) 664-672;
    2. Pharmacologic differentiation between inositol-1,4,5-trisphosphate-induced Ca2+ release and Ca2+- or caffeine-induced Ca2+ release from intracellular membrane systems.
      P Palade, C Dettbarn, B Alderson and P Volpe
      Molecular Pharmacology October 1989, 36 (4) 673-680;

  2. Andreu, J M

    1. Cytoplasmic microtubules in human neutrophil degranulation: reversible inhibition by the colchicine analogue 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1- one.
      F Mollinedo, J M Nieto and J M Andreu
      Molecular Pharmacology October 1989, 36 (4) 547-555;

B

  1. Berstein, G

    1. Effect of the lipid environment on the differential affinity of purified cerebral and atrial muscarinic acetylcholine receptors for pirenzepine.
      G Berstein, T Haga and A Ichiyama
      Molecular Pharmacology October 1989, 36 (4) 601-607;

  2. Booth, G

    1. Glycoprotein nature of dopamine D1 receptors in the brain and parathyroid gland.
      K R Jarvie, G Booth, E M Brown and H B Niznik
      Molecular Pharmacology October 1989, 36 (4) 566-574;

  3. Bouvier, M

    1. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites.
      S B Liggett, M Bouvier, W P Hausdorff, B O'Dowd, M G Caron and R J Lefkowitz
      Molecular Pharmacology October 1989, 36 (4) 641-646;

  4. Braakman, I

    1. Zonal distribution of the cation lucigenin in rat liver: influence of taurocholate.
      I Braakman, O Verest, T Pijning, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 532-536;
    2. Vesicular uptake system for the cation lucigenin in the rat hepatocyte.
      I Braakman, T Pijning, O Verest, B Weert, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 537-542;

  5. Brown, E M

    1. Glycoprotein nature of dopamine D1 receptors in the brain and parathyroid gland.
      K R Jarvie, G Booth, E M Brown and H B Niznik
      Molecular Pharmacology October 1989, 36 (4) 566-574;

C

  1. Campbell, S F

    1. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
      R P Mason, S F Campbell, S D Wang and L G Herbette
      Molecular Pharmacology October 1989, 36 (4) 634-640;

  2. Caron, M G

    1. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites.
      S B Liggett, M Bouvier, W P Hausdorff, B O'Dowd, M G Caron and R J Lefkowitz
      Molecular Pharmacology October 1989, 36 (4) 641-646;

  3. Cassel, D

    1. 2-Iodoimipramine, a novel ligand for the serotonin transporter.
      C J Humphreys, D Cassel and G Rudnick
      Molecular Pharmacology October 1989, 36 (4) 620-626;

  4. Childers, S R

    1. Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes.
      C S Konkoy and S R Childers
      Molecular Pharmacology October 1989, 36 (4) 627-633;

  5. Commandeur, J N

    1. Bioactivation of the cysteine-S-conjugate and mercapturic acid of tetrafluoroethylene to acylating reactive intermediates in the rat: dependence of activation and deactivation activities on acetyl coenzyme A availability.
      J N Commandeur, F J De Kanter and N P Vermeulen
      Molecular Pharmacology October 1989, 36 (4) 654-663;

  6. Coutsogeorgopoulos, C

    1. Type of inhibition of peptide bond formation by chloramphenicol depends on the temperature and the concentration of ammonium ions.
      D L Kalpaxis and C Coutsogeorgopoulos
      Molecular Pharmacology October 1989, 36 (4) 615-619;

D

  1. Davies, M F

    1. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities.
      H O Villar, E T Uyeno, L Toll, W Polgar, M F Davies and G H Loew
      Molecular Pharmacology October 1989, 36 (4) 589-600;

  2. De Kanter, F J

    1. Bioactivation of the cysteine-S-conjugate and mercapturic acid of tetrafluoroethylene to acylating reactive intermediates in the rat: dependence of activation and deactivation activities on acetyl coenzyme A availability.
      J N Commandeur, F J De Kanter and N P Vermeulen
      Molecular Pharmacology October 1989, 36 (4) 654-663;

  3. Dettbarn, C

    1. Direct inhibition of inositol-1,4,5-trisphosphate-induced Ca2+ release from brain microsomes by K+ channel blockers.
      P Palade, C Dettbarn, P Volpe, B Alderson and A S Otero
      Molecular Pharmacology October 1989, 36 (4) 664-672;
    2. Pharmacologic differentiation between inositol-1,4,5-trisphosphate-induced Ca2+ release and Ca2+- or caffeine-induced Ca2+ release from intracellular membrane systems.
      P Palade, C Dettbarn, B Alderson and P Volpe
      Molecular Pharmacology October 1989, 36 (4) 673-680;

  4. Dingledine, R

    1. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      C J McBain, N W Kleckner, S Wyrick and R Dingledine
      Molecular Pharmacology October 1989, 36 (4) 556-565;

F

  1. Fahey, M A

    1. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.
      B K Madras, R D Spealman, M A Fahey, J L Neumeyer, J K Saha and R A Milius
      Molecular Pharmacology October 1989, 36 (4) 518-524;

  2. Foxwell, B M

    1. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.
      B M Foxwell, A Mackie, V Ling and B Ryffel
      Molecular Pharmacology October 1989, 36 (4) 543-546;

G

  1. Groothuis, G M

    1. Zonal distribution of the cation lucigenin in rat liver: influence of taurocholate.
      I Braakman, O Verest, T Pijning, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 532-536;
    2. Vesicular uptake system for the cation lucigenin in the rat hepatocyte.
      I Braakman, T Pijning, O Verest, B Weert, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 537-542;

  2. Gundersen, C B

    1. Mercuric ions are potent noncompetitive antagonists of human brain kainate receptors expressed in Xenopus oocytes.
      J A Umbach and C B Gundersen
      Molecular Pharmacology October 1989, 36 (4) 582-588;

H

  1. Haga, T

    1. Effect of the lipid environment on the differential affinity of purified cerebral and atrial muscarinic acetylcholine receptors for pirenzepine.
      G Berstein, T Haga and A Ichiyama
      Molecular Pharmacology October 1989, 36 (4) 601-607;

  2. Hausdorff, W P

    1. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites.
      S B Liggett, M Bouvier, W P Hausdorff, B O'Dowd, M G Caron and R J Lefkowitz
      Molecular Pharmacology October 1989, 36 (4) 641-646;

  3. Herbette, L G

    1. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
      R P Mason, S F Campbell, S D Wang and L G Herbette
      Molecular Pharmacology October 1989, 36 (4) 634-640;

  4. Hortin, G L

    1. Sulfation of tert-butoxycarbonylcholecystokinin and other peptides by rat liver tyrosylprotein sulfotransferase.
      S Rens-Domiano, G L Hortin and J A Roth
      Molecular Pharmacology October 1989, 36 (4) 647-653;

  5. Humphreys, C J

    1. 2-Iodoimipramine, a novel ligand for the serotonin transporter.
      C J Humphreys, D Cassel and G Rudnick
      Molecular Pharmacology October 1989, 36 (4) 620-626;

I

  1. Ichiyama, A

    1. Effect of the lipid environment on the differential affinity of purified cerebral and atrial muscarinic acetylcholine receptors for pirenzepine.
      G Berstein, T Haga and A Ichiyama
      Molecular Pharmacology October 1989, 36 (4) 601-607;

  2. Itzhak, Y

    1. Multiple affinity binding states of the sigma receptor: effect of GTP-binding protein-modifying agents.
      Y Itzhak
      Molecular Pharmacology October 1989, 36 (4) 512-517;

J

  1. Janssen, P A

    1. Ca2+-mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine.
      P J Pauwels, H P Van Assouw, J E Leysen and P A Janssen
      Molecular Pharmacology October 1989, 36 (4) 525-531;

  2. Jarvie, K R

    1. Glycoprotein nature of dopamine D1 receptors in the brain and parathyroid gland.
      K R Jarvie, G Booth, E M Brown and H B Niznik
      Molecular Pharmacology October 1989, 36 (4) 566-574;

K

  1. Kalpaxis, D L

    1. Type of inhibition of peptide bond formation by chloramphenicol depends on the temperature and the concentration of ammonium ions.
      D L Kalpaxis and C Coutsogeorgopoulos
      Molecular Pharmacology October 1989, 36 (4) 615-619;

  2. Kleckner, N W

    1. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      C J McBain, N W Kleckner, S Wyrick and R Dingledine
      Molecular Pharmacology October 1989, 36 (4) 556-565;

  3. Konkoy, C S

    1. Dynorphin-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes.
      C S Konkoy and S R Childers
      Molecular Pharmacology October 1989, 36 (4) 627-633;

L

  1. Lefkowitz, R J

    1. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites.
      S B Liggett, M Bouvier, W P Hausdorff, B O'Dowd, M G Caron and R J Lefkowitz
      Molecular Pharmacology October 1989, 36 (4) 641-646;

  2. Leysen, J E

    1. Ca2+-mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine.
      P J Pauwels, H P Van Assouw, J E Leysen and P A Janssen
      Molecular Pharmacology October 1989, 36 (4) 525-531;

  3. Liggett, S B

    1. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites.
      S B Liggett, M Bouvier, W P Hausdorff, B O'Dowd, M G Caron and R J Lefkowitz
      Molecular Pharmacology October 1989, 36 (4) 641-646;

  4. Ling, V

    1. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.
      B M Foxwell, A Mackie, V Ling and B Ryffel
      Molecular Pharmacology October 1989, 36 (4) 543-546;

  5. Loew, G H

    1. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities.
      H O Villar, E T Uyeno, L Toll, W Polgar, M F Davies and G H Loew
      Molecular Pharmacology October 1989, 36 (4) 589-600;

M

  1. Mackie, A

    1. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.
      B M Foxwell, A Mackie, V Ling and B Ryffel
      Molecular Pharmacology October 1989, 36 (4) 543-546;

  2. Madras, B K

    1. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.
      B K Madras, R D Spealman, M A Fahey, J L Neumeyer, J K Saha and R A Milius
      Molecular Pharmacology October 1989, 36 (4) 518-524;

  3. Marks, G S

    1. Evidence for the stereoselective inhibition of chick embryo hepatic ferrochelatase by N-alkylated porphyrins.
      S A McCluskey, R A Whitney and G S Marks
      Molecular Pharmacology October 1989, 36 (4) 608-614;

  4. Mason, R P

    1. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
      R P Mason, S F Campbell, S D Wang and L G Herbette
      Molecular Pharmacology October 1989, 36 (4) 634-640;

  5. McBain, C J

    1. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      C J McBain, N W Kleckner, S Wyrick and R Dingledine
      Molecular Pharmacology October 1989, 36 (4) 556-565;

  6. McCluskey, S A

    1. Evidence for the stereoselective inhibition of chick embryo hepatic ferrochelatase by N-alkylated porphyrins.
      S A McCluskey, R A Whitney and G S Marks
      Molecular Pharmacology October 1989, 36 (4) 608-614;

  7. Meijer, D K

    1. Zonal distribution of the cation lucigenin in rat liver: influence of taurocholate.
      I Braakman, O Verest, T Pijning, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 532-536;
    2. Vesicular uptake system for the cation lucigenin in the rat hepatocyte.
      I Braakman, T Pijning, O Verest, B Weert, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 537-542;

  8. Milius, R A

    1. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.
      B K Madras, R D Spealman, M A Fahey, J L Neumeyer, J K Saha and R A Milius
      Molecular Pharmacology October 1989, 36 (4) 518-524;

  9. Molinoff, P B

    1. Effects of polyamines on the binding of [3H]MK-801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site.
      K Williams, C Romano and P B Molinoff
      Molecular Pharmacology October 1989, 36 (4) 575-581;

  10. Mollinedo, F

    1. Cytoplasmic microtubules in human neutrophil degranulation: reversible inhibition by the colchicine analogue 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1- one.
      F Mollinedo, J M Nieto and J M Andreu
      Molecular Pharmacology October 1989, 36 (4) 547-555;

N

  1. Neumeyer, J L

    1. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.
      B K Madras, R D Spealman, M A Fahey, J L Neumeyer, J K Saha and R A Milius
      Molecular Pharmacology October 1989, 36 (4) 518-524;

  2. Nieto, J M

    1. Cytoplasmic microtubules in human neutrophil degranulation: reversible inhibition by the colchicine analogue 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1- one.
      F Mollinedo, J M Nieto and J M Andreu
      Molecular Pharmacology October 1989, 36 (4) 547-555;

  3. Niznik, H B

    1. Glycoprotein nature of dopamine D1 receptors in the brain and parathyroid gland.
      K R Jarvie, G Booth, E M Brown and H B Niznik
      Molecular Pharmacology October 1989, 36 (4) 566-574;

O

  1. O'Dowd, B

    1. Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites.
      S B Liggett, M Bouvier, W P Hausdorff, B O'Dowd, M G Caron and R J Lefkowitz
      Molecular Pharmacology October 1989, 36 (4) 641-646;

  2. Otero, A S

    1. Direct inhibition of inositol-1,4,5-trisphosphate-induced Ca2+ release from brain microsomes by K+ channel blockers.
      P Palade, C Dettbarn, P Volpe, B Alderson and A S Otero
      Molecular Pharmacology October 1989, 36 (4) 664-672;

P

  1. Palade, P

    1. Direct inhibition of inositol-1,4,5-trisphosphate-induced Ca2+ release from brain microsomes by K+ channel blockers.
      P Palade, C Dettbarn, P Volpe, B Alderson and A S Otero
      Molecular Pharmacology October 1989, 36 (4) 664-672;
    2. Pharmacologic differentiation between inositol-1,4,5-trisphosphate-induced Ca2+ release and Ca2+- or caffeine-induced Ca2+ release from intracellular membrane systems.
      P Palade, C Dettbarn, B Alderson and P Volpe
      Molecular Pharmacology October 1989, 36 (4) 673-680;

  2. Pauwels, P J

    1. Ca2+-mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine.
      P J Pauwels, H P Van Assouw, J E Leysen and P A Janssen
      Molecular Pharmacology October 1989, 36 (4) 525-531;

  3. Peroutka, S J

    1. Three-dimensional steric molecular modeling of the 5-hydroxytryptamine3 receptor pharmacophore.
      A W Schmidt and S J Peroutka
      Molecular Pharmacology October 1989, 36 (4) 505-511;

  4. Pijning, T

    1. Zonal distribution of the cation lucigenin in rat liver: influence of taurocholate.
      I Braakman, O Verest, T Pijning, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 532-536;
    2. Vesicular uptake system for the cation lucigenin in the rat hepatocyte.
      I Braakman, T Pijning, O Verest, B Weert, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 537-542;

  5. Polgar, W

    1. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities.
      H O Villar, E T Uyeno, L Toll, W Polgar, M F Davies and G H Loew
      Molecular Pharmacology October 1989, 36 (4) 589-600;

R

  1. Rens-Domiano, S

    1. Sulfation of tert-butoxycarbonylcholecystokinin and other peptides by rat liver tyrosylprotein sulfotransferase.
      S Rens-Domiano, G L Hortin and J A Roth
      Molecular Pharmacology October 1989, 36 (4) 647-653;

  2. Romano, C

    1. Effects of polyamines on the binding of [3H]MK-801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site.
      K Williams, C Romano and P B Molinoff
      Molecular Pharmacology October 1989, 36 (4) 575-581;

  3. Roth, J A

    1. Sulfation of tert-butoxycarbonylcholecystokinin and other peptides by rat liver tyrosylprotein sulfotransferase.
      S Rens-Domiano, G L Hortin and J A Roth
      Molecular Pharmacology October 1989, 36 (4) 647-653;

  4. Rudnick, G

    1. 2-Iodoimipramine, a novel ligand for the serotonin transporter.
      C J Humphreys, D Cassel and G Rudnick
      Molecular Pharmacology October 1989, 36 (4) 620-626;

  5. Ryffel, B

    1. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein.
      B M Foxwell, A Mackie, V Ling and B Ryffel
      Molecular Pharmacology October 1989, 36 (4) 543-546;

S

  1. Saha, J K

    1. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.
      B K Madras, R D Spealman, M A Fahey, J L Neumeyer, J K Saha and R A Milius
      Molecular Pharmacology October 1989, 36 (4) 518-524;

  2. Schmidt, A W

    1. Three-dimensional steric molecular modeling of the 5-hydroxytryptamine3 receptor pharmacophore.
      A W Schmidt and S J Peroutka
      Molecular Pharmacology October 1989, 36 (4) 505-511;

  3. Spealman, R D

    1. Cocaine receptors labeled by [3H]2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane.
      B K Madras, R D Spealman, M A Fahey, J L Neumeyer, J K Saha and R A Milius
      Molecular Pharmacology October 1989, 36 (4) 518-524;

T

  1. Toll, L

    1. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities.
      H O Villar, E T Uyeno, L Toll, W Polgar, M F Davies and G H Loew
      Molecular Pharmacology October 1989, 36 (4) 589-600;

U

  1. Umbach, J A

    1. Mercuric ions are potent noncompetitive antagonists of human brain kainate receptors expressed in Xenopus oocytes.
      J A Umbach and C B Gundersen
      Molecular Pharmacology October 1989, 36 (4) 582-588;

  2. Uyeno, E T

    1. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities.
      H O Villar, E T Uyeno, L Toll, W Polgar, M F Davies and G H Loew
      Molecular Pharmacology October 1989, 36 (4) 589-600;

V

  1. Van Assouw, H P

    1. Ca2+-mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine.
      P J Pauwels, H P Van Assouw, J E Leysen and P A Janssen
      Molecular Pharmacology October 1989, 36 (4) 525-531;

  2. Verest, O

    1. Zonal distribution of the cation lucigenin in rat liver: influence of taurocholate.
      I Braakman, O Verest, T Pijning, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 532-536;
    2. Vesicular uptake system for the cation lucigenin in the rat hepatocyte.
      I Braakman, T Pijning, O Verest, B Weert, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 537-542;

  3. Vermeulen, N P

    1. Bioactivation of the cysteine-S-conjugate and mercapturic acid of tetrafluoroethylene to acylating reactive intermediates in the rat: dependence of activation and deactivation activities on acetyl coenzyme A availability.
      J N Commandeur, F J De Kanter and N P Vermeulen
      Molecular Pharmacology October 1989, 36 (4) 654-663;

  4. Villar, H O

    1. Molecular determinants of benzodiazepine receptor affinities and anticonvulsant activities.
      H O Villar, E T Uyeno, L Toll, W Polgar, M F Davies and G H Loew
      Molecular Pharmacology October 1989, 36 (4) 589-600;

  5. Volpe, P

    1. Direct inhibition of inositol-1,4,5-trisphosphate-induced Ca2+ release from brain microsomes by K+ channel blockers.
      P Palade, C Dettbarn, P Volpe, B Alderson and A S Otero
      Molecular Pharmacology October 1989, 36 (4) 664-672;
    2. Pharmacologic differentiation between inositol-1,4,5-trisphosphate-induced Ca2+ release and Ca2+- or caffeine-induced Ca2+ release from intracellular membrane systems.
      P Palade, C Dettbarn, B Alderson and P Volpe
      Molecular Pharmacology October 1989, 36 (4) 673-680;

W

  1. Wang, S D

    1. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
      R P Mason, S F Campbell, S D Wang and L G Herbette
      Molecular Pharmacology October 1989, 36 (4) 634-640;

  2. Weert, B

    1. Vesicular uptake system for the cation lucigenin in the rat hepatocyte.
      I Braakman, T Pijning, O Verest, B Weert, D K Meijer and G M Groothuis
      Molecular Pharmacology October 1989, 36 (4) 537-542;

  3. Whitney, R A

    1. Evidence for the stereoselective inhibition of chick embryo hepatic ferrochelatase by N-alkylated porphyrins.
      S A McCluskey, R A Whitney and G S Marks
      Molecular Pharmacology October 1989, 36 (4) 608-614;

  4. Williams, K

    1. Effects of polyamines on the binding of [3H]MK-801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site.
      K Williams, C Romano and P B Molinoff
      Molecular Pharmacology October 1989, 36 (4) 575-581;

  5. Wyrick, S

    1. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes.
      C J McBain, N W Kleckner, S Wyrick and R Dingledine
      Molecular Pharmacology October 1989, 36 (4) 556-565;
Back to top

In this issue

Advertisement